Mode
Text Size
Log in / Sign up
Phase 4 Completed N=11 Treatment

Long-Duration Stimulant Treatment Study of ADHD in Young Children

Attention Deficit Disorder With Hyperactivity
Source: ClinicalTrials.gov NCT00257725 ↗
Enrolled (actual)
11
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcomePrimary: Swanson, Nolan, and Pelham Questionnaire (SNAP-IV) — -1.09 score on a scale — p=0.01
◆ Published Evidence
Established
26citations · ~2 / year
The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate.
Journal of child and adolescent psychopharmacology · 2009 · Open access · High-confidence link

Summary

This study will evaluate if Ritalin LA™ is safe and effective for ADHD treatment in 4-to-5-year olds.

Linked Publications

  • The open-label treatment of attention-deficit/hyperactivity disorder in 4- and 5-year-old children with beaded methylphenidate.
    Journal of child and adolescent psychopharmacology · 2009 · 26 citations · Open access · High-confidence link

Outcome Measures

OutcomeResultp-value
PRIMARY
Swanson, Nolan, and Pelham Questionnaire (SNAP-IV)
-1.09 0.01 sig
PRIMARY
Clinical Global Impressions-Severity (CGI-S)
-1.64 0.01 sig
PRIMARY
Children's Global Assessment Scale (C-GAS)
10.55 0.01 sig

Eligibility Criteria

Inclusion Criteria

  • Parents/guardians and children must speak English and/or Spanish; parents/guardians must sign consent form; children must verbally assent.
  • Boys and girls from 4-5 years old (inclusive) at screening.
  • Children who meet the DSM-IV criteria for a primary diagnosis of ADHD (combined or hyperactive subtype), with symptoms present for at least 9 months.
  • Children who demonstrate adequate need for treatment due to ADHD symptom-severity and clinical impairment.
  • Children with IQ of at least 70 confirmed by valid IQ test.
  • Children who are in educational settings (pre-school, kindergarten, or elementary school program) with at least 8 same-age peers for at least two half days weekly.
  • Parents and children who can attend weekly study visits.
  • Children who are naïve to ADHD medications; received ADHD medications in the past but are not currently treated; or on ADHD medications but finding them inconvenient (due to short duration of action) or not very helpful

Exclusion Criteria

  • Children and parents/guardians who do not understand or cannot follow necessary instructions; children and parents who are unwilling to comply with study procedures or cooperate with child psychiatrist.
  • Children taking excluded medications.
  • Children with history of intolerance to MPH/stimulant medications or no response to adequate stimulant trials.
  • Children with current adjustment disorder, autism, psychosis, bipolar disorder, significant suicidality, or other psychiatric disorders.
  • Children with history of physical, sexual, or emotional abuse, which lead to a significant impact on the clinical presentation and potentially some ADHD symptoms.
  • Children with screening abnormalities deemed clinically significant by child psychiatrist.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00257725) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search